Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 2/2015

01-02-2015 | Diabetes and Pregnancy (CJ Homko, Section Editor)

Using Oral Agents to Manage Gestational Diabetes: What Have We Learned?

Authors: Elizabeth Buschur, Florence Brown, Jennifer Wyckoff

Published in: Current Diabetes Reports | Issue 2/2015

Login to get access

Abstract

Insulin has been the mainstay of treatment of diabetes during pregnancy for decades. Although glyburide and metformin are classified as category B during pregnancy, recent research has suggested that these oral agents alone or in conjunction with insulin may be safe for the treatment of gestational diabetes (GDM). This paper summarizes the data on the use of glyburide and metformin for treatment of GDM.
Literature
1.
2.
3.
Langer O et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(16):1134–8.CrossRefPubMed
4.
5.
Ogunyemi DA et al. Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). Diabet Med. 2011;28(8):976–86.CrossRefPubMed
6.
Tattersall R. Diabetes: the biography. Oxford: Oxford University Press; 2009.
7.
8.
9.
Douglas CP, Richards R. Use of chlorpropamide in the treatment of diabetes in pregnancy. Diabetes. 1967;16(1):60–1.CrossRefPubMed
10.
Notelovitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J. 1971;45(9):226–9.PubMed
11.
12.
13.
Kemball ML et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child. 1970;45(243):696–701.CrossRefPubMedCentralPubMed
14.
Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics. 1968;42(5):824–5.PubMed
15.
Uhrig JD, Hurley RM. Chlorpropamide in pregnancy and transient neonatal diabetes insipidus. Can Med Assoc J. 1983;128(4):368. 370–1.PubMedCentralPubMed
16.
Christesen H, Melander A. Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. Eur J Endocrinol. 1998;138(6):698–701.CrossRefPubMed
17.
18.
Ramos GA et al. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007;27(5):262–7.CrossRefPubMed
19.
Coetzee EJ, Jackson WPU. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract. 1985;1(5):281–7.CrossRefPubMed
20.
Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17(7):507–11.CrossRefPubMed
21.
Elliott BD et al. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol. 1991;165(4 Pt 1):807–12.CrossRefPubMed
22.
Elliott BD et al. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol. 1994;171(3):653–60.CrossRefPubMed
23.
Gedeon C et al. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006;27(11–12):1096–102.CrossRefPubMed
24.
Nanovskaya TN et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med. 2008;21(3):197–207.CrossRefPubMed
25.
Koren G. Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol. 2001;15(3):227–9.CrossRefPubMed
26.
Zharikova OL et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol. 2009;78(12):1483–90.CrossRefPubMedCentralPubMed
27.
Ke AB et al. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol. 2014;77(3):554–70.CrossRefPubMed
28.
Kraemer J et al. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol. 2006;195(1):270–4.CrossRefPubMed
29.
Pollex EK et al. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos. 2010;38(5):740–4.CrossRefPubMed
30.
Hemauer SJ et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010;202(4):383.e1–7.
31.
Iqbal M et al. Placental drug transporters and their role in fetal protection. Placenta. 2012;33(3):137–42.CrossRefPubMed
32.
Hebert MF et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther. 2009;85(6):607–14.CrossRefPubMedCentralPubMed
33.
Lim JM et al. A comparison between the pregnancy outcome of women with gestation diabetes treated with glibenclamide and those treated with insulin. Med J Malays. 1997;52(4):377–81.
34.
Goetzl L, Wilkins I. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis. J Perinatol. 2002;22(5):403–6.CrossRefPubMed
35.
Jacobson GF et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005;193(1):118–24.CrossRefPubMed
36.
Rochon M et al. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol. 2006;195(4):1090–4.CrossRefPubMed
37.
Holt RIG et al. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab. 2008;10(10):906–11.CrossRefPubMed
38.
Mathews JE et al. Retrospective cohort study comparing neonatal outcomes of women treated with glyburide or insulin in gestational diabetes: a 5-year experience in a South Indian teaching hospital. Indian J Med Sci. 2011;65(11):476–81.CrossRefPubMed
39.
Yogev Y et al. Glyburide in gestational diabetes—prediction of treatment failure. J Matern Fetal Neonatal Med. 2011;24(6):842–6.CrossRefPubMed
40.
Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol. 2004;24(10):617–22.CrossRefPubMed
41.
Bertini Anna, M., et al., Perinatal outcomes and the use of oral hypoglycemic agents, in Journal of Perinatal Medicine. 2005. p. 519.
42.•
Cheng YW et al. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes. J Matern Fetal Neonatal Med. 2012;25(4):379–84. This is a large retrospective study of glyburide use in GDM. It is useful as it illustrates the outcomes of the real life application of glyburide in GDM.
43.
Langer O et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol. 2005;192(1):134–9.CrossRefPubMed
44.
Lain KY et al. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol. 2009;200(5):501.e1–6.
45.
Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. J Obstet Gynaecol Res. 2013;39(6):1147–52.CrossRefPubMed
46.
Anjalakshi C et al. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract. 2007;76(3):474–5.CrossRefPubMed
47.•
Zeng Y-c et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis. Adv Med Sci. 2014;59(1):95–101. This is a meta-analysis of RCTs of glyburide versus insulin. Most RCTs on this topic are under-powered to detect differences in neonatal outcomes, hence, the importance of a meta-analysis of the topic.
48.
Wareing M et al. Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries. Placenta. 2006;27(6–7):660–8.CrossRefPubMed
49.
Petty RG, Pearson JD. The influence of hypoglycaemic agents on the growth and metabolism of human endothelial cells. Diabet Med. 1992;9(1):30–7.CrossRefPubMed
50.
51.
Ballas J, Moore TR, Ramos GA. Management of diabetes in pregnancy. Curr Diabetes Rep. 2012;12(1):33–42.CrossRef
52.
Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Prac Res Clin Obstet Gynaecol. 2011;25(1):51–63.CrossRef
53.
Cassina, M., et al., First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Human Reproduction Update, 2014.
54.
Rowan JA, Mi GI. A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial). Diabetes Care. 2007;30 Suppl 2:S214–9.CrossRefPubMed
55.
Rowan JA et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed
56.
Feig DS. Metformin therapy for gestational diabetes mellitus: are we there yet? Nat Clin Pract Endocrinol Metab. 2008;4(12):654–5.CrossRefPubMed
57.
58.••
Rowan JA et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84. This is the most recent paper in a very important series by these authors reporting on the use of metformin in GDM and the long-term outcomes on offspring.
59.
Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med. 2011;28(9):1082–7.CrossRefPubMed
60.
Hickman MA et al. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol. 2013;30(6):483–90.CrossRefPubMed
61.
Ekpebegh CO et al. A 10-year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med. 2007;24(3):253–8.CrossRefPubMed
62.
Tertti K et al. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud. 2008;5(2):95–101.CrossRefPubMedCentralPubMed
63.
Gandhi P et al. Introduction of metformin for gestational diabetes mellitus in clinical practice: has it had an impact? Eur J Obstet Gynecol Reprod Biol. 2012;160(2):147–50.CrossRefPubMed
64.
Balani J et al. Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med. 2009;26(8):798–802.CrossRefPubMed
65.
Mesdaghinia E et al. Comparison of newborn outcomes in women with gestational diabetes mellitus treated with metformin or insulin: a randomised blinded trial. Int J Prev Med. 2013;4(3):327–33.PubMedCentralPubMed
66.
Moore LE et al. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010;115(1):55–9.CrossRefPubMed
67.
Silva JC et al. Metformin compared with glyburide for the management of gestational diabetes. Int J Gynecol Obstet. 2010;111(1):37–40.CrossRef
68.
Zarate A et al. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex. 2000;68:42–5.PubMed
69.
Wilton LV et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882–9.CrossRefPubMed
Metadata
Title
Using Oral Agents to Manage Gestational Diabetes: What Have We Learned?
Authors
Elizabeth Buschur
Florence Brown
Jennifer Wyckoff
Publication date
01-02-2015
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 2/2015
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0570-5

Other articles of this Issue 2/2015

Current Diabetes Reports 2/2015 Go to the issue

Diabetes and Pregnancy (CJ Homko, Section Editor)

Impact of Gestational Diabetes Mellitus in the Maternal-to-Fetal Transport of Nutrients

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston, Section Editor)

Material Need Support Interventions for Diabetes Prevention and Control: a Systematic Review

Diabetes and Pregnancy (CJ Homko, Section Editor)

Review of Impacts of Physical Activity on Maternal Metabolic Health During Pregnancy

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

From Pathobiology to the Targeting of Pericytes for the Treatment of Diabetic Retinopathy

Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)

Type 2 Diabetes in Youth in South Asia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits